Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2005

Identification of the Pla2 Responsible For Prostanoid Synthesis in
Response to Inflammatory Cytokines
Chaminda Fernando
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Biochemistry, Biophysics, and Structural Biology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/803

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

O Charninda Fernando 2005

All Rights Reserved

...

111

IDENTIFICATION OF THE PLA;! RESPONSIBLE FOR PROSTANOID SYNTHESIS
IN RESPONSE TO INFLAMMATORY CYTOKINES

A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

by
CHAMINDA FERNANDO
Bachelor of Science, University of Maryland, College Park, 2001

Director: CHARLES E. CHALFANT, Ph.D.
ASSISTANT PROFESSOR
DEPARTMENT OF BIOCHEMISTRY

Virginia Commonwealth University
Richmond, Virginia
August, 2005

Acknowledgements

I would like to extend my heartfelt appreciation and thanks to my mentor and

advisor, Dr. Charles Chalfant, for his guidance, enthusiasm, and great sense of humor.
I would also like to thank all the members of the Chalfant lab, the greatest group of

people anyone could ask for.
Thank you to my committee members, Dr. George Ford and Dr. Mohammed
Kalimi, for their advice and guidance since the time I started the certificate program.
Last, but not least, thank you to my family for their unconditional love and support,
which has made all of this possible.

Table of Contents
Page
List of Tables.....................................................................................................................

..
vll

...

List of Figures .................................................................................................................. vill

. .

List of Abbreviations.......................................................................................................... ix
Abstract ............................................................................................................................... x
Chapter
1

Introduction .......................................................................................................

2

Materials and Methods ............. ........................... ................ . . .

1

. . . . . . 15

2.1 Maintenance of A549 Human Adenocarcinoma Cells ......................... 15
2.2 siRNA Transfection .............................................................................. 15
2.3 Treatment with Cytokines ........................................ . . .

. .......... . 17

2.4 WST-1 Assay ........................................................................................ 17
2.5 Enzyme Linked immuno Sorbent Assay (ELISA) ............................... 17
2.6 Western Immunoblotting Against cPLA2a........................................... 19
3

Results .............................................................................................................

21

3.1 Optimization of the Media Used in the Transfection of A549 Cells with
siRNA ............................. ............

. . . . . . . . . . . . . .. . . . .. . . 21

3.2 Optimization of the Transfection Protocol for siRNA ......................... 24
3.3 Optimization of the Stable Maintenance of PGE2 Production in A549
Cells ...................................................................................................... 24
3.4 cPLA2a siRNA Down Regulates Target Protein ................................. 25

vi
3.5 cPLA2a Regulates PGE2 Generation at Basal Levels and In Response to
Inflammatory Cytokines ....................................................................... 25
3.6 cPLA2y, cPLA26, and iPLA2 regulate the basal levels of PGE2 production
and cPLA2p is not involved in prostanoid synthesis in A549 cells ...... 26
4

Discussion ....................................................................................................... 31

References .........................................................................................................................

35

Vita ....................................................................................................................................

39

vii

List of Tables
Page
Table 1: Classification of Phospholipases. .........................................................................9

viii

List of Figures
Page
Figure 1: Prostaglandin Biosynthesis is Carried Out by Most Cells of the Body ...............4
Figure 2: Eicosanoid Biosynthesis ...................................................................................... 5
Figure 3: Hydrolysis of Membrane Phospholipids ............................................................. 7
Figure 4: Structure of PLA2 Isoforms ...............................................................................

11

Figure 5: C- 1.P. the "Missing Link" in Inflammatory Agonist Mediated Eicosanoid
Biosynthesis.......................................................................................................

13

Figure 6: Optimized Protocol Used to Transfect A549 Cells with siRNA ....................... 22
Figure 7: Transferring the Media Collected from the Cytokine Treated Cells on to an
ELISA Plate to Quantitate PGE2........................................................................ 23
Figure 8: Down Regulation of cPLA2aby RNAi Transfection ........................................ 27
Figure 9: Down Regulation of PLA2 Isoforms Using RNAi Transfection Resulted in
Decreased PGE2Production.............................................................................. 28
Figure 10: Down Regulation of cPLA2Phas no Effect on PGE2 Production ................... 30

List of Abbreviations

AA
ATCC
C-1-P
CaLB
COX
cPLA2
ELISA
IL-1s
iPLA2
NSAIDS
PAF
PGE2
RNAi
SIC
siRNA
SMase D
sPLA2
TNFa

Arachidonic acid
American Type Culture Collection
Ceramide-1-phosphate
Calcium Dependent Lipid Binding Domain
Cyclooxygenase
Cytosolic Phospholipase A2
Enzyme Linked Immuno Sorbent Assay
Interleukin-1 beta
Calcium independent Phospholipase A2
Non-Steroidal Anti-Inflammatory Drugs
Platelet Activating Factor
Prostaglandin E2
RNA interference
Standard Incubator Conditions
small interfering RNA
Sphingomyelinase D
secreted Phospholipase A2
Tumor Necrosis Factor-alpha

Abstract

IDENTIFICATION OF THE PLA2 RESPONSIBLE FOR PROSTANOID SYNTHESIS

IN RESPONSE TO INFLAMMATORY CYTOKINES
By Chaminda Fernando
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Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2005

Major Director: Charles E. Chalfant, Ph.D.
Assistant Professor, Department of Biochemistry

Preliminary studies from our laboratory showed that cPLA2a may be responsible
for approximately 50-60% of the PGE2production in response to inflammatory cytokines.
Thus, we hypothesized that a closely-related PLA2 is responsible for 40-50% of the PGE2
produced in response to inflammatory cytokines. To this end, we utilized RNAi
technology, extensively optimized, to down regulate the expression of closely-related
isoforms of phospholipase A2 in A549 cells and used an enzyme linked immuno sorbent
assay (ELISA) to quantitate the PGE2 produced. These studies found that cytosolic
phospholipase A2a (cPLA2a)regulated 97.7% of the prostaglandin E2(PGE2) produced in
response to inflammatory cytokines (e.g. IL-1P or TNFa), as well as regulating the basal
levels of this prostanoid. Furthermore, cPLA2y, cPLA26, and iPLA2 were found to also

xi
regulate the basal levels of PGE2production. On the other hand, cPLA2P was not involved
in prostanoid synthesis in A549 cells either in the presence or absence of inflammatory
cytokines. Thus, our studies show that cPLA2aplays the pivotal role in the production of
PGE2 in response to inflammatory cytokines, and suggests that cPLA2a may be a possible
drug target in diseases such as asthma, inflammation, and cancer.

1. Introduction

Inflammation is the first response of the immune system to infection or
irritation. The symptoms of inflammation are characterized by rubor (redness), calor
(heat), tumor (swelling), and dolor (pain), which have been known since the ancient times
[I]. The study of the signal transduction pathway leading to inflammation has recently
flourished due to the relationship of inflammation diseases to cancer, arteriosclerosis, and
Alzheimer's disease [2-51. Recent studies have revealed that prostaglandins and
leukotrienes operate as key intra- and inter-cellular inflammatory mediators. These
bioactive lipids are produced as a result of the catalytic activity on arachidonic acid (AA)
by cyclooxygenases (COX) to produce prostaglandins and by lipoxygenases to produce
leukotrienes [6]. Initially, it was thought that the AA cascade was a constitutively active
pathway generating prostaglandins for homeostatic functions such as maintenance of the
renal blood flow and protection of the gastric lining [7]. This concept soon changed with
the discovery of an inducible form of COX, COX-2, which led the former form of COX
to be called COX-1; both of which are inhibited by aspirin and other forms of nonsteroidal anti-inflammatory drugs [8]. Studies have shown that COX- 1 is responsible for
basal level prostanoid synthesis and COX-2 is important in various inflammatory settings
and cancer [8,9].

Prostaglandins were first isolated from semen in the 1930s, and it was thought
that these bioactive lipids were synthesized in the prostate gland, hence the name
prostaglandin. Since then many studies have shown that prostaglandins are produced in
almost all the cells of the body and that they play a pivotal role in mediating disease
states such as inflammation, thrombosis, diabetes, and cancer [lo]. They are also
responsible for the promotion or inhibition of normal bodily functions such as
vasodilation, blood clotting, ion transport, cell growth, lipolysis, and immune system
response (figure 1). Prostaglandins belong to a subclass of lipids known as eicosanoids
because of their structural similarities to the C-20 polyunsaturated fatty acids, the
eicosanoic acids. Soon after the synthesis of prostaglandins, they are released from cells
through facilitated transport and act in an autocrine or paracrine manner due to their short
half lives (seconds to a few minutes) [8]. Therefore, prostaglandins must be synthesized
as needed and are not stored free in tissues, and are one of the most potent natural
substances known [I, 111. The same prostaglandin can have different functions depending
upon the receptor form on the surrounding cells [8]. Several types of prostaglandins are
produced in the body based upon subtle differences in their structure and the most
abundant COX-2 product is prostaglandin E2 (PGE2), and its levels are used as a measure
of phospholipase activation.
The binding of cytokines or growth factors to cell receptors or mechanical trauma
can initiate a cascade of events leading to the activation of a group of very important

enzymes known as the phospholipases. The hydrolysis of cell membrane lipids by
phospholipases facilitates the release of AA, which is the precursor to prostaglandins and
leukotrienes, from phospholipids, and this is the initial rate-limiting step in the eicosanoid
biosynthetic pathways [12-151. The enzymes, COX-1 and COX-2, act on the released
arachidonic acid to begin the prostaglandin synthetic pathway (Figure 2).
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FIGURE 1. Prostaglandin biosynthesis is carried out by most cells of the body (FU
D, Collin. Lipid Biology 2001,294: 1872)
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FIGURE 2. Eicosanoid biosynthesis. Activated PLA2 releases arachidonic acid
by hydrolysis of membrane phospholipids. Arachidonic acid can be utilized by either
lipoxygenases to generate leukotrienes or by cyclooxygenases (COX-1 and COX-2) to
generate the intermediate, PGG2followed by PGH2.The activity of prostacyclin synthase,
PGE synthase, PGD synthase, PGF synthase, and thromboxane synthase gives rise to
prostaglandins and thromboxanes.

Phospholipase A2 (PLA2) enzymes specifically catalyze the hydrolysis of the sn-2
ester bond of phospholipids to release free fatty acids and lysophospholipids (Figure 3)
[12,15,16]. Therefore, this group of enzymes plays a critical role in cellular lipid
metabolism, thereby regulating energy storage, membrane remodeling, and the
production of potent inflammatory mediators (e.g. prostaglandins and leukotrienes) in
response to inflammatory cytokines such as IL- 1P and TNFa.
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Figure 3. Hydrolysis of membrane phospholipids. Activated PLA2s cleaves
membrane phospholipids at the sn-2 position to release arachidonic acid. The catalytic
reactions of cyclooxygenases ultimately lead to the production of prostaglandins. The
cyclooxygenases are inhibited by non-steroidal anti-inflammatory drugs (NSAIDS).

Mammalian cells contain structurally diverse forms of PLA2, classified into
groups I, 11, 111, IV, V, VI, VII, VIII, IX, X, XI, and XI1 (Table 1) [16,17]. Functionally,
these groups are recombined into four types of PLA2s: secreted PLA2 (sPLA2), which are
stored in cytosolic granules or synthesized upon stimulation and then secreted
extracellularly, consisting of groups I, 11, 111, V, IX, X, XI, and XII; cytosolic PLA2
(cPLA~),which are located in the cytosol and translocated into the membrane, consisting
of groups IVA, IVB, IVC, and IVDelta; calcium independent PLA2 (iPLA2), which are
located both in the cytosol and in membrane fractions, consisting of groups VIA, and
VIB; and platelet-activating factor (PAF) acetylhydrolases consisting of groups VII
and VIII [18-201. The cPLA2 family of phospholipases is further divided into four
isoforms, cPLA2a (group IVA), cPLA2P (group IVB), cPLA2y (group IVC), and cPLA26
(group IVDelta).

TYpe

Group

Ca++dependent
binding to
membranes

Notes

Secreted PLA2
(sPLA2)

I, 11, 111, V, IX,X,
XI, XI1

-

Cytosolic PLA2
(cPLA2)

IVA, IVB, IVC,
IVDelta

cPLA2a-Yes
cPLA2P-Yes
cPLA26-Yes
cPLA2y-No

Calcium
independent
(iPLA2)
Platelet Activating
Factor (PAF)
Acetylhydrolases

VIA, VIB

No

Stored in cytosolic
granules or
synthesized upon
stimulation and then
secreted
extracellularly
Located in cytosol
and translocated
into membrane,
except for cPLA2y,
which is membrane
bound
Located both in
cytosol and
membrane fractions

VII, VIII

-

-

Table 1. Classification of phospholipases.
The cDNAs of human PLA2 isoforms, cPLA2a, cPLA2P, cPLA2y, cPLA26, and
iPLA2 encode polypeptides of 749, 1012, 541, 8 18, and 782 amino acids, respectively.
Close examination of the primary structures of the group IV isoforms reveal sequence
homology among the members, which can be related to the amino acid sequence of
iPLA2 (figure 4). The mRNA for cPLA2 is widely expressed in the brain, lung, kidney,
heart, and spleen [21-241. All 5 of the phospholipases contain two catalytic domains, A
and B, with gene-unique sequences separating the domains. The amino acid residues that

are important for catalytic activity of cPLA2a, Arg200, Ser228, Asp549, and Arg566, are
all conserved in cPLA~P,cPLA2y, and cPLA26 [25-271. Mutagenesis studies have shown
that amino acid residues Ser483 (catalytic domain A) and Asp627 (catalytic domain B) in
iPLA2 are involved in catalytic activity and that these residues are homologous to Ser228
and Asp549 in cPLA2a [ 181.
Numerous findings on the structure of cPLA2a, cPLA2P, and cPLA26 have
revealed that there is a 120 amino acid sequence near the N-terminus that encodes for the
calcium-dependent lipid binding domain (C2lCaLB) [28-301. In cPLA2P and cPLA26
there are 120 and 135 amino acid inserts, respectively, between the C2 domain and
catalytic domain A. However, in cPLA2a, the C2 domain and the catalytic domain A are
adjacent to each other. The C2lCaLB domain functions to facilitate the calciumdependent binding of cPLA2a, cPLA2P, and cPLA26 to membranes. Studies have shown
that calcium, at physiologically relevant concentrations, is required for the translocation
of these cPLA2 isoforms from the cytosol to the cellular membranes. Numerous studies
have revealed that calcium binding to the C2 domain functions as an electrostatic switch.
Thus, calcium binding decreases the polarity on the surface of this domain by
neutralizing negative charges and promotes penetration of hydrophobic residues into the
membrane interior [24]. In contrast, cPLA2y is calcium-independent and is farnesylated at
the C-terminus, which facilitate this enzyme to bind to membranes.

C ~ L BCatalytic domain A

ms515

Catalytic
domain B

@

~727

Farnesylation
I

Figure 4. Structure of PLA2 isoforrns. All PLA2 isoforms carry 2 catalytic
domains, A and B. The amino acid residues essential for catalytic activity, Arg200,
Ser228, Asp549, and Arg566, are all conserved in cPLA2a, cPLA2P, cPLA2y, and cPLA26.

In iPLA2, amino acid residues Ser483 in catalytic domain A and Asp627 in catalytic
domain B are involved in catalytic activity. These residues are homologous to Ser228 and
Asp549 in cPLA2a. The C2lCaLB domain found in cPLA2a, cPLA2P, and cPLA26
facilitates the calcium dependent translocation of these enzymes to Golgilperinuclear
regions. cPLA2y is membrane bound through farnesylation at the C-terminus.

Research has shown that there is an essential component interacting with the
CaLB domain of cPLA2, which can regulate the membrane association of cPLA2.
Ceramide- 1-phosphate (C-1-P), formed by the phosphorylation of ceramide by ceramide
kinase is one such lipid regulator of cPLA2 and interestingly ceramide kinase has similar
tissue distribution as cPLA2 (Figure 5) [11,22]. In other studies, the main component of
the venom from the brown recluse spider, Loxosceles reclusa, is the enzyme
sphingomyelinase D (SMase D) [11,3 11. SMase D is responsible for the hydrolysis of
sphingomyelin to produce C-1-P and the bite of this spider causes an intense
inflammatory response mediated by arachidonic acid and prostaglandins. This led our
laboratory to hypothesize that C-1-P may function as a pathophysiologic link in the
activation of cPLA2 and the inflammatory response mediated by arachidonic acid and
prostaglandins and that there might be a mammalian counterpart to SMaseD, which led to
the discovery of a biology for the enzyme, cerarnide kinase.

INFLAMMATION

Figure 5. C-1-P, the "missing link" in inflammatory agonist mediated eicosanoid
biosynthesis. Binding of inflammatory agonists to cell membrane receptors activates

ceramide kinase resulting in the production of C-1-P, which goes on to activate cPLA2,
cPLA2 hydrolyses membrane phospholipids to release arachidonic acid and this step can
be inhibited by steroids. The released arachidonic acid is utilized by COX-2, which is
inhibited by NSAIDS, to produce prostanoids ultimately resulting in inflammation.

Published results from our laboratory establish ceramide kinase and subsequent
C-1-P production as a "missing link" in eicosanoid biosynthesis in response to
inflammatory agonists [11,22,23,]. This data is important because they revealed a specific
biology regulated by C-1-P. In the same study, our laboratory showed that downregulation of ceramide kinase decreased arachidonic acid release implicating that C-1-P
is required for arachidonic acid release in response to inflammatory agonists [ I l l .
Furthermore, C-1-P induced translocation of full-length cPLAz from the cytosol to the
Golgi apparatuslperinuclear regions, and cPLA2 siRNA completely inhibited the
induction of arachidonic acid release by C-1-P [ l 11. Unpublished findings disclose that
cPLA2a is responsible for approximately 50-60% of the production of PGE2. Thus, we
hypothesized that cPLA~P,cPLA2y, cPLA26, or iPLA2 are responsible for the remaining
40-50% of the PGE2 production, and are possible targets for C- 1-P.

2. Materials and Methods

2.1 Maintenance of A549 Human Adenocarcinoma Cells
A549 cells, thawed from cultures stored in liquid nitrogen (freeze media: 10%
sterile DMSO, 40% FBS, 50% supplemental media), were obtained from American Type
Culture Collection (ATCC). The cells were grown in 250 mL canted, vented tissue
culture flasks (Falcon) containing A549 culture media. This media is composed of 50%
DMEM

(Invitrogen)

supplemented

with

L-glutamine,

50%

RPMI 1640 (Invitrogen), 100 UIrnL of penicillin G sodium (Invitrogen), 100 pg1mL of
streptomycin sulfate (Invitrogen), and 10% (vlv) heat inactivated fetal bovine serum
(Invitrogen). Cell cultures were maintained at 37' C in a Heraeus incubator with 5% C 0 2
(verified by gas analyzer) and 95% humidity (Standard Incubator Conditions (SIC)). For
experiments, cells were counted using trypan blue dye and a hemocytometer (Fisher
Scientific) and plated on 24-well plates at 1 . 2 5 ~ 1 0cells1mL
~
per treatment. The 24-well
plate was incubated overnight at SIC.

2.2 siRNA Transfection
The plate was observed under an inverted microscope the following day in order
ensure that the cells were in the confluency range of 4.0-70% prior to siRNA transfection.
The media was removed and each well was washed with 1 mL of Optimem (Invitrogen).
Then, 200 pL of optimem were added to each well, and the plate was returned to SIC.
The siRNA reagent, Dharmafect (Dharmacon), was prepared by diluting 2 pL of
Dharmafect per treatment with 5.5 pL of optimem per treatment. This solution was
incubated at room temperature for 10 minutes. siRNA (Dharmacon) 20pM stock
solutions were made by adding 250 pL of 1X Dharmacon siRNA buffer to 5 nmol of
lyophilized siRNA. Then, 2.5 pL per treatment of a respective siRNA stock solution was
diluted in 40 pL per treatment of Optimem and the diluted Dharmafect was added to each
siRNA solution at 7.5 pL per treatment. The solutions were mixed by pippeting up and
down gently three times, and the siRNADharmafect complex was incubated at room
temperature for 15-20 minutes. After the incubation period, the siRNADharmafect mix
was added drop wise to the appropriate wells at 50 pL per well. The plate was swirled
gently to mix well and then placed at SIC for 4 hours. Following the incubation period,
125 pL of 3X growth media (1.8% Penicillin/Streptomycin, 30% Fetal Bovine Serum,
68.2% Optimem) was added to each well and returned to standard incubation conditions
for 24 hours. After the incubation period, A549 media was added to each well and the
plate was gently swirled to mix, which was followed by removal of the media. 1 mL of

A549 media was then added to each well, and the cells were returned to standard
incubation conditions for 24 hours.

2.3 Treatment with Cytokines
On the day of the treatment, the cells were rinsed twice with resting media (2%
Fetal Bovine Serum, 96.2% DMEM, 1.8% Penicillin/Streptomycin) and the cells were
observed for any changes in confluency andfor morphology. The cytokines, IL-1P and
TNFa were diluted in resting media at 5 ng/mL and 10 ng/mL, respectively. The media
was removed and resting media with the appropriate cytokine was added to each well at 1
mL per well. The control wells received equal amounts of PBS diluted in resting media
(sham control). The plate was incubated at SIC.

2.4 WST-1 Assay
Following cytokine treatment, 750 pL of media from each well was collected. To
the remaining 250 pL of media in the wells, 25 pL of WST-1 reagent (Roche
Diagnostics) was added and the plate was placed back in the incubator for 30 minutes.
After the incubation period, the optical density in each well of the plate was measured (at
450 nM vs. a reference of 630 nM) using microplate spectrophotometer (BIO-TEK KC
Junior). These data were used to normalize the proceeding PGE2 results.

2.5 Enzyme Linked Immuno Sorbent Assay (ELISA)
The standard was prepared by obtaining eight 1.5 mL microfuge tubes and
numbering them #1 through #8. To tube #1, 180 pL of 1 in 40 dilution resting media in
1X EIA buffer (Cayman Chemical) was added. To tubes #2 through #8, 100 pL of the
same solution was added. Next, 20 pL of the standard PGE2 (Cayman Chemical) was
added to tube #I and mixed thoroughly. In order to serially dilute the samples, 100 pL
was removed from tube #1 and placed in tube #2 and mixed thoroughly, from tube #2
100 pL was removed and placed in tube #3 and mixed thoroughly. This process was
repeated until standard #8. The ELISA plate (Cayman Chemical), coated with goat antimouse IgG was loaded at 50 pL per well of standardlsample, where the sample was
diluted at 1 in 40 (sample : 1X EIA), 50 pL of PGE2 EIA AChE tracer (Cayman
Chemical), and 50 pL of PGE2 monoclonal antibody (Cayman Chemical). The control
wells received 50 pL of 1X EIA buffer along with 50 pL of PGE2 EIA AChE tracer and
50 pL of PGE2 monoclonal antibody. The plate was covered and placed in 4' C for 16
hours.
After the incubation period, all the liquid from the wells were removed and the
plate was washed with wash buffer (Cayman Chemical) five times. Next, 200 pL of
Ellman's reagent (Cayman Chemical) was added to each well and the plate was covered
and allowed to develop in the dark with low shaking at room temperature for 90 minutes.

Following the developing step, absorbance in each well at 405 nM was read using a
microplate spectrophotometer (BMG Labtech FLUOStar Optima). Wells containing
Ellman's reagent alone served as the blank for absorbance background.

2.6 Western Immunoblotting Against cPLAza
A549 cells were counted using trypan blue exclusion counting, and were plated
into 6-well plates at 2 . 5 ~10' cells135 mm well (4 mL total media) per treatment. The 6well plate was incubated overnight at SIC. The plate was observed under an inverted
microscope the following day in order ensure that the cells were in the confluency range
of 40-70% prior to siRNA transfection. The media was removed and each well was
washed with 1 mL of Optimem. Then, 600 pL of Optimem were added to each well and
the plate was placed back in the incubator. Next, 7.5 pL per treatment of its respective
siRNA 20 pM stock solution was diluted in 120 pL per treatment of Optimem. The
siRNA reagent, Dharmafect (Dharmacon), was prepared by diluting 6 pL of Dharmafect
per treatment with 16.5 pL of optimem per treatment. This solution was incubated at
room temperature for 10 minutes. Then, the diluted Dharmafect was added to each
siRNA solution at 22.5 pL per treatment. The solutions were mixed by pippeting up and
down gently three times. These siRNA1Dharmafect complexes were incubated at room
temperature for 15-20 minutes. After the incubation period, the siRNA/Dharmafect mix
was added drop wise to the appropriate wells at 150 pL per well. The plate was swirled

gently to mix well and then placed at SIC for 4 hours. Following the incubation period,
375 pL of 3X growth media was added to each well, and the plate was returned to SIC for
24 hours. On the following day, the cells were observed for any changes in confluency
andlor morphology. Then, 1 mL of A549 media was added to each well and the plate was
gently swirled to mix. Next, the media was removed, and 1 mL of A549 media was added
to each well. The plate was returned to SIC for an additional 24 hours. After 24 hours, the
cells were lifted using a cell lifter, and the media with the cells were transferred into 15
mL conical tubes. The tubes were centrifuged at 4' C under low speed in order to pellet
the cells, and the supernatant was discarded. The cell pellet was washed with 1X cold
PBS and the tube was centrifuged again. The supernatant was discarded, and the cell
pellet was re-suspended in 100 pL of 1X cold PBS and transferred to 1.5 mL microfuge
tubes with screw caps. Next, 100 pL of 2X lysis buffer (200 p.L 1X Binding buffer, 10 pL
Leupeptin, 1 pL Aproprotinin, 5 pL Pepstatin, 10 pL PMSF, 100 pL Glycerol) was
added to the tubes, and the samples were boiled for 10 minutes.
30 pL of the total protein lysate was subjected to 10% SDS-PAGE. Proteins were
transferred to polyvinylidene difluoride membrane (Bio-Rad) and blocked in 5% milk,
1 x PBS-T (M-PBS-T) for 2 h. The membrane was incubated with anti-cPLA2a polyclonal goat IgG (Santa Cruz Biotechnology) or anti-a-tubulin mouse mono-clonal IgM
(Santa Cruz Biotechnology) for 2 h in M-PBS-T followed by 3 washes with PBS-T. The
membrane was then incubated with a secondary antibody of horseradish peroxidase-

conjugated affinipure donkey anti-goat IgG (anti-cPLA2a) (Jackson Imrnuno Research
Labs Inc.) or horseradish peroxidase-conjugated anti-mouse IgM (Cal-Biochem) (anti-atubulin) for 45 min followed by 3 washes with PBS-T. Immunoblots were developed
using Pierce ECL reagents and Bio-Max film.

3. Results

3.1 Optimization of the media used in the transfection of A549 cells with siRNA
Initially, we used DMEM as the media to wash the cells prior to transfection and
to incubate the cells that have been transfected with siRNA. We observed that most of the
cells in the center of the wells died just 24 hours post-transfection. Evidently, DMEM
proved to be toxic to RNAi transfected cells. Then, we replaced the DMEM with
optimem for the washing and incubation steps and the cell survival rate increased
dramatically. Thus, optimem was used as the media of choice in the transfection of A549
cells with siRNA.

simA

24-well plate

i

Figure 6. Optimized protocol used to transfect A549 cells with siRNA

J

96-well ELISA Plate

V

Figure 7. Transferring the media collected from the cytokine treated cells on to an

ELISA plate to quantitate PGE2.

3.2 Optimization of the transfection protocol for siRNA
During the initial stages of the project, we were using Oligofectamine transfection
reagent (Invitrogen) to introduce siRNA to A549 cells. This protocol generated very good
results until the manufacturer changed the reagent, causing non-reproducible results. We
examined Dharmafect, the RNAi transfection reagent manufactured by the same
company that produces siRNA, as a vehicle to introduce siRNA into A549 cells. This
transfection reagent worked very effectively to generate reproducible results, and
Dharmacon siRNA transfection protocol is the standard protocol now used by the
Chalfant laboratory.

3.3 Optimization of the stable maintenance of PGE2 production in A549 cells
One of the obstacles that we had to overcome was the elevated basal levels of
PGE2 production from the non-cytokine treated A549 cells. We attributed this to over
stressing the cells. We incorporated a washout step with A549 complete media 24 hours
post-transfection to overcome the elevated basal PGE2 production. This resulted in
relatively low basal PGE2 levels. Thus, this step was incorporated into the siRNA
transfection protocol.

3.4 cPLA2a siRNA down-regulates target protein
To determine if cPLA2a was downregulated by RNAi transfection, a Western
immunoblot utilizing an anti-cPLA2a antibody was used. The normalized densitometry
data indicated that cPLA2a was down-regulated by approximately 83% (figure 8). The
data demonstrated that siRNA was specific to cPLA2a and that down-regulation of
cPLA2a was not due to any off-target effects of siRNA. Furthermore, siRNA to the
closely related cPLA26 and iPLA2 had no effect on cPLA2a levels, also demonstrating
specificity. Therefore, the transfection was successful and cPLA2a siRNA actually downregulated the target protein.

3.5 cPLA2a regulates PGE2 generation at basal levels and in response to
inflammatory cytokines
Preliminary data from our laboratory inferred that cPLA2a may be responsible for
approximately 50-60% of PGE2 production in response to inflammatory cytokines, but
the RNAi technology was not optimized. To further verify this finding, and determine the
percentage of PGE2 produced in response to inflammatory cytokines regulated by
cPLA2a, RNAi transfection was again employed to down regulate the expression of
cPLA2a. An optimized ELISA, to quantitate the PGE2 produced, specifically
demonstrated that siRNA targeted to cPLA2a inhibited approximately 80% of the PGE2
produced in response to either IL-1P or TNFa. Normalizing this percentage of inhibition

to the percentage of down regulation of cPLA2a indicated that 96.4% of the PGE2
produced in response to inflammatory cytokines was due to cPLA2a. Furthermore,
siRNA targeted to cPLA2a inhibited 95.6% of the basal levels of PGE2 (figure 9).

3.6 cPLA2y, cPLA26, and iPLA2 regulate the basal levels of PGE2 production and
cPLA2p is not involved in prostanoid synthesis in A549 cells
According to preliminary data, 50-60% of PGE2 produced in A549 cells in
response to inflammatory cytokines was regulated by cPLA2a, thus we hypothesized that
the remaining 40-50% is produced by cPLA2P, cPLA2y, cPLA26, or iPLA2. As stated
above, optimization of the siRNA transfection demonstrated that approximately 100% of
the PGE2 produced in response to inflammatory cytokines was due to cPLA2a. To further
verify this finding, RNAi technology was utilized to down regulate the aforementioned
PLA2 isoforms individually. cPLA2y, cPLA26, and iPLA2 inhibited the basal level of
PGE2 production, but as expected these phospholipases had no effect on cytokine
mediated production of PGE2 (figure 8). In addition to the above findings, the data
indicated that cPLA2P did not have a role in the cytokine induced or the basal level of
PGE2 production (figure 10). Therefore, these findings verify that cPLA2a is the PLA2
responsible for PGE:! production in response to inflammatory cytokines as down
regulation of closely related PLA2s had no effect. Furthermore, possible roles for iPLA2,
cPLA2y cPLA26in basal PGE2 synthesis have been implicated.

Recombinant
cPLA2a-V5-6XHis (+ Ctrl)

cPLA2a

a Tubulin

I 1 1 1 1
Figure 8. Down regulation of cPLA2a by RNAi transfection. Cells were transfected
with respective siRNA and cell lysates were subjected to 10% SDS-PAGE analysis,
transferred to a polyvinylidene difluoride membrane, and immunoblotted as described in
"material and methods" section. The top panel shows the down regulation of cPLA2a in
cells transfected with siRNA as compared to cells transfected with control, iPLA2, and
cPLA26 siRNA. The bottom panel shows the blot normalized with a tubulin.
Recombinant cPLA2a-V5-6XHis was used as positive control. This figure is
representative of two independent experiments.

Figure 9. Down regulation of PLA2 isoforms using RNAi transfection resulted in
decreased PGE2 production. Cells were transfected with siRNA and treated with IL-1P
(IL), TNFa (TNF), or PBS (-) as described in the "material and methods" section; Ctrl

IL = transfected with control siRNA and treated with IL-1P; Ctrl TNF = transfected with
control siRNA and treated with TNFa; Ctrl- = transfected with control siRNA and
treated with PBS; Alpha IL = transfected with cPLA2a siRNA and treated with IL-1P;

Alpha TNF = transfected with cPLA2a siRNA and treated with TNFa; Alpha- =
transfected with cPLA2a siRNA and treated with PBS; Gamma IL = transfected with
cPLA2y siRNA and treated with IL- 1P; Gamma TNF = transfected with cPLA2y siRNA
and treated with TNFa; Gamma- = transfected with cPLA2y siRNA and treated with
PBS; Delta IL = transfected with cPLA26 siRNA and treated with IL-ID; Delta TNF =
transfected with cPLA26 siRNA and treated with TNFa; Delta- = transfected with

cPLA26 siRNA and treated with PBS; i IL = transfected with iPLA2 siRNA and treated
with IL-1P; i TNF = transfected with iPLA2 siRNA and treated with TNFa; i- =
transfected with iPLA2 siRNA and treated with PBS. This figure is representative of two
independent experiments.
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Figure 10. Down regulation of cPLA2$ has no effect on PGE2 production. Cells were
transfected with siRNA and treated with IL-1P (+) or PBS (-) as described in the
"material and methods" section; Ctrl + = transfected with control siRNA and treated with
IL- 1P; Ctrl- = transfected with control siRNA and treated with PBS; Beta + = transfected
with cPLA2P siRNA and treated with IL-1P; Beta

- = transfected with cPLAzP siRNA

and treated with PBS. This figure is representative of two independent experiments.

4. Discussion

Unpublished findings from our laboratory disclosed that cPLA2a may be
responsible for 50-60% of the PGE2 produced in response to inflammatory cytokines. In
this study, we optimized an RNAi protocol and identified cPLA2a to be involved in
approximately 100% of the PGE2 production in A549 cells stimulated with inflammatory
cytokines. We also showed that cPLA2a, cPLA2y, cPLA2F, and iPLA2 may play roles in
basal prostanoid synthesis, and that cPLA2P is not involved in the prostanoid synthetic
pathway in A549 cells. The importance of these findings is as follows: First, cPLA2a has
been confirmed as the major regulator of PGE2 synthesis in response to inflammatory
cytokines in line with previously reported findings involving lipopolysaccharides (LPS)
and calcium ionophore, A23 187. Second, siRNA targeting cPLA2a can be developed as a
potential therapeutic agent against asthma. Finally, phospholipases may have
implications as new drug targets against asthma, inflammation and cancer therapies.
Initially, we spent approximately 8 months on optimizing the protocols that were
used in this study. First, when we used DMEM to wash the cells prior to the transfection
with siRNA, we observed that most of the cells in the center of the wells died just 24
hours post-transfection. We were able to overcome this obstacle by replacing DMEM,
which proved to be toxic to RNAi transfected cells, with Optimem and the cell survival
rate increased dramatically. Next, we were using Oligofectamine transfection reagent
32

(Invitrogen) to introduce siRNA to A549 cells. This protocol, at first, produced a
reproducible result, until the manufacturer changed the reagent and protocol for siRNA
delivery, causing non-reproducible results. Thus, we examined Dharmafect, the RNAi
transfection reagent manufactured by the same company that produces siRNA, and
reproducible results were obtained from this reagent. Another obstacle that we overcame
was the elevated basal levels of PGE2 production from the non-cytokine treated A549
cells, which may have been due to over stressing the cells by transfection. We
incorporated a washout step with A549 complete media 24 hours post-transfection to
overcome the elevated basal PGE2 production. Finally, allowing for significant
observations in cytokine response, an assay for RNAi use in examining PGE2 production
was generated giving very reproducible results, which is now the "Gold standard used in
the Chalfant laboratory.
As aforementioned, unpublished studies from our laboratory demonstrated that
cPLA2a may play a role in the production of 50-60% of PGE2 in A549 cells treated with
inflammatory cytokines. This led to our initial hypothesis that the closely-related PLA2s,
cPLA2P, cPLA2y, cPLA26, or iPLA2, may be responsible for the remaining 40-50% of the
PGE2 production. By utilizing RNAi technology and down-regulating cPLA2a, we have
demonstrated that cPLA2a actually is responsible for approximately 100% of the PGE2
synthesized in response to treatment with cytokines. Furthermore, studies using
osteoblastic bone marrow stromal cells from cPLA2a knockout mice indicated that

cPLA2a played a key role in PGE2 production, in response to lipopolysaccharide (LPS)

[24,31]. Our studies have similar effects on PGE2 production by cPLA2a in response to
extracellular mediators. In addition, other PLA2 isoforms examined in this study had no
involvement in cytokine mediated PGE2 synthesis.
These individual PLA2 isoforms, cPLA2a, cPLA2y, cPLA26, and iPLA2, may be
involved in basal prostanoid synthesis. In addition, this study revealed that downregulation of cPLA2P did not have any significant change in the production of PGE2 in
the presence or absence of cytokines. Thus, a function for cPLA2P is still elusive.
The findings from this study are also important for several other reasons. First,
understanding the individual enzymes involved in the cascade of steps leading to
prostanoid synthesis following the envenomation of a brown recluse spider can result in a
new treatment regiment to the spider bite. Furthermore, these findings may shed light to
the mysterious recurrence of necrotic and hemolytic effects proximal to the brown recluse
envenomation site several months after the bite. Second, these findings can lead to the
development of siRNA as a potential therapeutic agent, in the form of an inhaler, against
asthma. Finally, identification of the most important phospholipases in the prostanoid
synthetic pathway can lead to new drug targets in treating asthma, inflammation and
cancer. Thus, better understanding of the role of cPLA2a in the inflammatory pathway
can lead to a new approach to bone disease by inhibiting cPLA2a, especially with the

newly discovered cardiac risks associated with selective COX-2 inhibitors such as
Celebrex and Vioxx.
In conclusion, these results demonstrate cPLA2a as the phospholipase A2
responsible for the PGE2 production in response to inflammatory cytokines. Furthermore,
these results also demonstrate that cPLA2a, along with cPLA2y, cPLA26, and iPLA2 are
all involved in basal prostanoid synthesis and that cPLA2Pplays no part in the prostanoid
synthetic pathway in the presence or absence of cytokines. These findings may have
implications in better understanding the pathophysiology of a brown recluse spider bite,
incorporating RNAi technology as a potential pharmacological tool, and giving rise to
new targets for anti-asthma, anti-inflammatory and anti-cancer therapies.
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